ID: ALA2385578

Max Phase: Preclinical

Molecular Formula: C20H14N4OS

Molecular Weight: 358.43

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(-c2cnc3c(-c4ccnc5ccsc45)cnn3c2)cc1

Standard InChI:  InChI=1S/C20H14N4OS/c1-25-15-4-2-13(3-5-15)14-10-22-20-17(11-23-24(20)12-14)16-6-8-21-18-7-9-26-19(16)18/h2-12H,1H3

Standard InChI Key:  IYOTVZSFTHIXBA-UHFFFAOYSA-N

Associated Targets(non-human)

Bone morphogenetic protein 4 32 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 358.43Molecular Weight (Monoisotopic): 358.0888AlogP: 4.68#Rotatable Bonds: 3
Polar Surface Area: 52.31Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 2.62CX LogP: 3.83CX LogD: 3.83
Aromatic Rings: 5Heavy Atoms: 26QED Weighted: 0.47Np Likeness Score: -1.47

References

1. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR..  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.,  23  (11): [PMID:23639540] [10.1016/j.bmcl.2013.03.113]

Source